Valeant Pharma (VRX), Walgreens Distribution Deal Structure Seen as 'Unusual'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/5/2026
- Dow closes at record on Mideast optimism; SpaceX, AMD drag Nasdaq
- SpaceX tumbles amid AI spending concerns; Musk outlines $1 trillion revenue target
- AMD shares slide 8% after Musk flags plans to buy Nvidia chips for SpaceX
- AZN spikes 6% after report it denies AstraZeneca-BMS merger talks
- New report warns China transceiver ban would hurt U.S. AI giants
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Opendoor posts Q2 revenue rise as net loss widens year over year
- Salesforce president Srini Tallapragada steps down, becomes advisor
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- Dave & Buster's names CFO Darin Harper as new CEO
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
Valeant Pharmaceuticals (VRX) Guidance 'Probably Conservative' - BMO Capital
December 16, 2015 8:09 AM ESTBMO Capital analyst Alex Arfaei said after a first look at Valeant Pharmaceuticals (NYSE: VRX) guidance he views it at "probably conservative."
Arfaei commented, "While some components of the guidance may appear disappointing, we suspect that it is conservative. About 7.2% of... More
QLT, Inc. (QLTI) Files Breach of Contract Lawsuit Against ValeantPharma (VRX)
December 16, 2015 7:01 AM ESTQLT Inc. (NASDAQ: QLTI) announced that it has filed a breach of contract lawsuit against Valeant Pharmaceuticals International, Inc. (NYSE: VRX) in the Supreme Court of British Columbia. QLT alleges that Valeant has failed to pay the $5 Million laser... More
Valeant Pharma (VRX) Trims Q4, FY15 Outlook; Offers FY16 Guidance
December 16, 2015 6:04 AM ESTValeant Pharmaceuticals International, Inc. (NYSE: VRX) announced updated financial guidance for the fourth quarter and full year 2015 as well as new guidance for full year 2016.
"We are very excited about the strong future given our broad portfolio of brands, our upcoming launch products and our robust R&D pipeline," said J. Michael Pearson, chairman and chief executive officer. "We believe that we are entering a new era of growth and opportunity as we continue to build and grow our businesses around the world and deliver... More
